Treatment of systemic hypertension in cats with amlodipine besylate

J Am Anim Hosp Assoc. May-Jun 1997;33(3):226-34. doi: 10.5326/15473317-33-3-226.

Abstract

Amlodipine besylate, a calcium channel blocker, was used to treat (mean +/- standard deviation [SD], 127 +/- 68 days) 12 cats with systemic hypertension. Amlodipine was administered orally at a dosage of 0.625 mg per cat (range, 0.08 to 0.23 mg/kg body weight; mean dose +/- SD, 0.17 +/- 0.04 mg/kg body weight) once daily as a single agent. Average indirect systolic blood pressure measurements in the 12 cases decreased significantly from 198 to 155 mmHg during amlodipine treatment. Significant changes in body weight and serum creatinine and potassium concentrations were not detected. Amlodipine appears to be a safe and effective oral treatment for systemic hypertension in cats when used chronically once daily as a single agent.

MeSH terms

  • Administration, Oral
  • Amlodipine / adverse effects
  • Amlodipine / standards
  • Amlodipine / therapeutic use*
  • Animals
  • Antihypertensive Agents / adverse effects
  • Antihypertensive Agents / standards
  • Antihypertensive Agents / therapeutic use*
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Body Weight / drug effects
  • Body Weight / physiology
  • Calcium Channel Blockers / adverse effects
  • Calcium Channel Blockers / standards
  • Calcium Channel Blockers / therapeutic use*
  • Cat Diseases / blood
  • Cat Diseases / drug therapy*
  • Cat Diseases / physiopathology
  • Cats
  • Creatinine / blood
  • Dose-Response Relationship, Drug
  • Female
  • Hypertension / drug therapy
  • Hypertension / physiopathology
  • Hypertension / veterinary*
  • Male
  • Potassium / blood
  • Retrospective Studies

Substances

  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Amlodipine
  • Creatinine
  • Potassium